Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Pediatric Transplants

Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens

Abstract

To compare the outcome of hematopoietic stem cell transplantation (HSCT) in pediatric acute lymphoblastic leukemia (ALL) conditioned with two different regimens: (1) single dose of VP16 (60 mg/kg over 4 h) and total body irradiation (TBI; 1200 cGy, in six fractions) or (2) Cyclophosphamide 50 mg/kg over 1 h daily for 4 days followed by the same dose of TBI. One hundred and seven children with ALL received fully matched HSCT from 1990 to 2003 in the Hospital for Sick Children, Toronto. All received cyclosporin A and a short course of methotrexate for graft-versus-host disease (GVHD) prophylaxis. The VP16 group, there were 36 matched related donor transplants (MRD) and 26 matched unrelated donor transplants (MUD), and in the cyclophosphamide group there were 23 MRD and 22 MUD transplants. Neutrophil engraftment occurred at a median of 18 and 17 days for the VP16/TBI and the CY/TBI groups, respectively. The 3 year event-free survival and overall survival were 47±7 and 55±7% for those receiving VP16/TBI, and 51±8 and 53±8% for the CY/TBI group. There were no significant differences in the prevalence of acute or chronic GVHD and transplant-related mortality between the two groups. Both VP16/FTBI and CY/FTBI regimen are equally effective regimens.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Davies SM, Ramsay NK, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 340–347.

    Article  CAS  PubMed  Google Scholar 

  2. Ringden O, Labopin M, Tura S, Arcese W, Iriondo A, Zittoun R et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996; 93: 637–645.

    Article  CAS  PubMed  Google Scholar 

  3. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723–2730.

    CAS  PubMed  Google Scholar 

  4. Wachowiak J, Bettoni C, Lange A, Malicki J, Kaczmarek-Kanold M, Gluszak B et al. Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia. Acta Haematol Pol 1995; 26: 377–384.

    CAS  PubMed  Google Scholar 

  5. Shah AJ, Lenarsky C, Kapoor N, Crooks GM, Kohn DB, Parkman R et al. Busulfan and cyclophosphamide as a conditioning regimen for pediatric acute lymphoblastic leukemia patients undergoing bone marrow transplantation. J Pediatr Hematol Oncol 2004; 26: 91–97.

    Article  PubMed  Google Scholar 

  6. Dai QY, Souillet G, Bertrand Y, Galambrun C, Bleyzac N, Manel AM et al. Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Bone Marrow Transplant 2004; 34: 667–673.

    Article  CAS  PubMed  Google Scholar 

  7. Blume KG, Long GD, Negrin RS, Chao NJ, Kusnierz-Glaz C, Amylon MD . Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14 (Suppl 4): S9–S10.

    PubMed  Google Scholar 

  8. Amylon MD, Co JP, Snyder DS, Donaldson SS, Blume KG, Forman SJ . Allogeneic bone marrow transplant in pediatric patients with high-risk hematopoietic malignancies early in the course of their disease. J Pediatr Hematol Oncol 1997; 19: 54–61.

    Article  CAS  PubMed  Google Scholar 

  9. Suttorp M, Schmitz N, Leuschner S, Appelt M, Rister M, Schaub J . Fractionated total body irradiation plus high-dose VP-16 prior to allogeneic bone marrow transplantation in children with poor risk acute leukaemias. Bone Marrow Transplant 1989; 4 (Suppl 4): 144–148.

    PubMed  Google Scholar 

  10. Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant 1997; 3: 324–330.

    CAS  PubMed  Google Scholar 

  11. Duerst RE, Horan JT, Liesveld JL, Abboud CN, Zwetsch LM, Senf ES et al. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide. Bone Marrow Transplant 2000; 25: 489–494.

    Article  CAS  PubMed  Google Scholar 

  12. Toubai T, Tanaka J, Mori A, Hashino S, Kobayashi S, Ota S et al. Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies. Clin Transplant 2004; 18: 552–557.

    Article  PubMed  Google Scholar 

  13. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832–843, 895–902.

    Article  CAS  PubMed  Google Scholar 

  14. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H et al. A controlled trial of fluconazole to prevent infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–851.

    Article  CAS  PubMed  Google Scholar 

  15. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD . Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 18: 173–178.

    Article  Google Scholar 

  16. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA . Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized-blind study. Blood 1996; 88: 4063–4071.

    CAS  PubMed  Google Scholar 

  17. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestation of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  18. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM . Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1989; 4: 247–254.

    CAS  PubMed  Google Scholar 

  19. Schwerdtfeger R, Schmid H, Baurmann H, Kleiner S, Zeiler T, Henze G et al. VP16 and TBI as conditioning regimen for allogeneic BMT in patients with high risk and relapsed ALL and NHL. Bone Marrow Transplant 1991; 7 (Suppl 2): 131.

    PubMed  Google Scholar 

  20. Kosaka Y, Koh K, Kinukawa N, Wakazono Y, Isoyama K, Oda T et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 2004; 104: 3527–3534.

    Article  CAS  PubMed  Google Scholar 

  21. Sanders JE, Im HJ, Hoffmeister PA, Gooley TA, Woolfrey AE, Carpenter PA et al. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 2005; 105: 3749–3756.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Jamieson CH, Amylon MD, Wong RM, Blume KG . Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: a 15-year experience. Exp Hematol 2003; 31: 981–986.

    Article  PubMed  Google Scholar 

  23. Dopfer R, Henze G, Bender-Gotze C, Ebell W, Ehninger G, Friedrich W et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Blood 1991; 78: 2780–2784.

    CAS  PubMed  Google Scholar 

  24. Locatelli F, Zecca M, Messina C, Rondelli R, Lanino E, Sacchi N et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 2002; 16: 2228–2237.

    Article  CAS  PubMed  Google Scholar 

  25. Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Bregante S et al. Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse. Haematologica 1998; 83: 896–903.

    CAS  PubMed  Google Scholar 

  26. Gustafsson Jernberg A, Remberger M, Ringden O, Winiarski J . Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival. Bone Marrow Transplant 2003; 31: 175–181.

    Article  CAS  PubMed  Google Scholar 

  27. Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000; 95: 1572–1579.

    CAS  PubMed  Google Scholar 

  28. Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, Messina C et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 2002; 100: 1192–1200.

    Article  CAS  PubMed  Google Scholar 

  29. Nordlander A, Mattsson J, Ringden O, Leblanc K, Gustafsson B, Ljungman P et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2004; 10: 195–203.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A Gassas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gassas, A., Sung, L., Saunders, E. et al. Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens. Bone Marrow Transplant 38, 739–743 (2006). https://doi.org/10.1038/sj.bmt.1705515

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705515

Keywords

This article is cited by

Search

Quick links